Barbara E. Murray, MD
Roberto C. Arduino, MD
Lisa Y. Armitige, MD, PhD
Ben J. Barnett, MD
Tanvir K. Bell, MD
Agathe Bourgogne, PhD
Herbert L. Dupont, MD
Charles D. Ericsson, MD
Sreedhar R. Nallapareddy, PhD
Pablo C. Okhuysen, MD
Luis Ostrosky-Zeichner, M.D., FACP, FIDSA
Kavindra Vikram Singh, Ph.D.

 

Barbara E. Murray, MD

DIRECTOR

Professor of Medicine

Director, Division of Infectious Diseases

Director, Center for the Study of Emerging and Re-emerging Pathogens

Vice chair for Research, Department of Medicine

 

Barbara E. Murray, MD is a 1969 cum laude graduate in mathematics from Rice University in Houston, Texas, and graduated first in her class (Ho Din Award and AOA) from the University of Texas Southwestern Medical School in Dallas in 1973. She then spent 6 years training in Internal Medicine and Infectious Diseases at Harvard Medical School’s Massachusetts General Hospital, in Boston, followed by 6 months in Thailand conducting research at the Armed Forces Research Institute of Medical Sciences. She joined the faculty at the University of Texas-Houston Medical School as an assistant professor in 1980, rising through the ranks to Professor by 1990, became Director of the Division of Infectious Diseases in 1995, and the J. Ralph Meadows Professor in 2003. She is also co-director of the UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens.

Dr. Murray is a nationally and internationally recognized expert in infectious diseases, microbiology and bacterial pathogenesis, conducts NIH funded research (including a current MERIT award), has served on a number of NIH committees and study sections, including as past Chair of the NIH Recombinant DNA Advisory Committee, as well as on the FDA’s Anti-Infectives Advisory Committee; she has also served on a number of Advisory Boards as a consultant to the pharmaceutical industry. She is past chair (3 year term) of the Program Planning Committee of the American Society of Microbiology’s ICAAC meeting, the world’s largest infectious diseases meeting; she served a 10-year term as an editor of Antimicrobial Agents and Chemotherapy, a journal published by the American Society of Microbiology; she currently serves on the Program Committee of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and is a frequent visiting professor at other medical schools and a frequent invited speaker at national and international meetings. Dr. Murray is an active member of the Infectious Diseases Society of America and is its Secretary-Treasurer.

Dr. Murray’s laboratory's broad interests involve the genetic and biochemical mechanisms of resistance to antibiotics and bacterial pathogenicity, particularly relating to enterococci, and molecular epidemiologic typing methods. Recent acquisition of antibiotic resistance traits have led enterococci to be called antibiotic resistant "super bugs" because of the lack of commercially available effective antibiotics. Work in her laboratory has included the first description of enterococci producing beta-lactamase, the first enterococci with high level resistance to all aminoglycosides, and the first enterococcal gentamicin resistance transposon. Work in pathogenicity, funded by two NIH grants, has been directed towards defining the enterococcal factors that contribute to infection, generation of isogenic mutants for studies of virulence, testing the potential protective effect of antiserum, identification of gene(s) encoding adherence to extracellular matrix proteins and characterization of a polysaccharide biosynthesis gene cluster of E. faecalis her group recently identified. Her recent description of E. faecalis pili (published in the Journal of Clinical Investigation) showed the importance of these structures to biofilm formation and experimental endocarditis and, subsequently, their importance in experimental urinary tract infection. There are active collaborations between her laboratory and the faculty in the Department of Microbiology and Molecular Genetics, the Center for Matrix Biology of TAMU, and the Human Genome Sequencing Center at BCM. Her research has resulted in over 200 papers in peer reviewed journals, as well as a number of reviews, chapters, and invited articles.

Peer reviewed publications since 2003:

• Rice LB, Carias L, Rudin S, Vael C, Goossens H, Konstabel C, Klare I, Nallapareddy SR, Huang W, Murray BE. A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis 187:508-512, 2003.
• Hubble TS, Hatton JF, Nallapareddy SR, Murray BE, Gillespie MJ. Influence of Enterococcus faecalis proteases and the collagen-binding protein, Ace, on adherence to dentin. Oral Microbiol Immunol 18:121-6, 2003.
• Nallapareddy SR, Weinstock GM, Murray BE. Clinical isolates of Enterococcus faecium exhibit strain-specific collagen-binding mediated by Acm, a new member of the MSCRAMM family. Mol Microbiol 47:1733-47, 2003.
• Nannini EC, Pai SR, Singh KV, Murray BE. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob Agents and Chemother 47:529-32, 2003.
• Waters CM, Antiporta MH, Murray BE, Dunny GM. Role of the Enterococcus faecalis GelE protease in determination of cellular chain length, supernatant pheromone levels, and degradation of fibrin and misfolded surface proteins. J Bacteriol 185:3613-23, 2003.
• Burman WJ, Breese PE, Murray BE, Singh KV, Batal H, MacKenzie T, Ogle J, Wilson ML, Reves RR, Mehler P. Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates. Amer J Med 115:358-64, 2003.
• Pai S, Singh KV, Murray BE. In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model. Antimicrob Agents and Chemother 47:2706-9, 2003.
• Teng F, Kawalec M, Weinstock GM, Hryniewicz W, Murray BE. An Enterococcus faecium secreted antigen, SagA, exhibits broad-spectrum binding to extracellular matrix (ECM) proteins and appears essential for growth. Infect Immun 71:5033-41, 2003.
• Nannini EC, Singh KV, Murray BE. Relapse of Type A lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: Revisiting the issue. Clin Infect Dis 37:1194-8, 2003.
• Zeng J, Teng F, Weinstock G, Murray BE. Translocation of Enterococcus faecalis strains across a monolayer of polarized human enterocyte-like T84 cells. J Clin Microbiol 42:1149-54, 2004.
• Roberts J, Singh K, Okhuysen PC, Murray BE. Molecular epidemiology of the fsr locus and of gelatinase production among different subsets of Enterococcus faecalis. J Clin Microbiol 42:2317-20, 2004.
• Mohamed J, Huang W, Nallapareddy S, Teng F, Murray BE. Influence of origin of isolates, especially endocarditis isolates, and various genes on biofilm formation by Enterococcus faecalis. Infect Immun 72:3658-63, 2004.
• Sillanpaa J, Xu Y, Nallapareddy S, Murray BE, Hook M. A family of putative MSCRAMMs from Enterococcus faecalis. Microbiol 150:2069-78, 2004.
• Pillai SK, Sakoulas G, Eliopoulos GM, Moellering RC, Murray BE, Inouye RT. Effects of glucose on fsr-mediated bioflm formation in Enterococcus faecalis. J Infect Dis 190:967-70, 2004.
• Singh KV and Murray BE. Differences in the Enterococcus faecalis lsa locus that influence susceptibility to quinupristin-dalfopristin and clindamycin. Antimicrob Agents and Chemother 49:32-39, 2005.
• Kawalec M, Potempa J, Moon JL, Travis J, Murray BE. Molecular diversity of a putative virulence factor: Purification and characterization of isoforms of an extracellular serine glutamyl endopeptidase of Enterococcus faecalis with different enzymatic activities. J Bacteriol 187:266-75, 2005.
• Teng F, Nannini EC, Murray BE. Importance of Gls24 in virulence and stress response of Enterococcus faecalis and use of the Gls24 protein as a possible immunotherapy target. J Infect Dis 191:472-80, 2005.
• Zeng J, Teng F, Murray BE. Gelatinase is important for translocation of Enterococcus faecalis across polarized human enterocyte-like T84 cells. Infect Immun 73:1606-12, 2005.
• Aakra A, Vebo H, Snipen L, Hirt, H, Aastveit A, Kapur V, Dunny G, Murray BE, Nes IF. Transcriptional response of Enterococcus faecalis V583 to erythromycin. Antimicrob Agents and Chemother 49:2246-2259, 2005.
• Murray BE, Anderson KE, Arnold K, Bartlett JG, Carpenter CC, Falkow S, Hartman JT, Lehman T, Reid TW, Ryburn FM Jr, Sack RB, Struelens MJ, Young LS, Greenough WB 3rd. Destroying the life and career of a valued physician-scientist who tried to protect us from plague: was it really necessary? Clin Infect Dis 40:1644-8, 2005.
• Singh KV, Nallapareddy S, Nannini E, Murray BE. Fsr independent production of protease(s) may explain the lack of attenuation of Enterococcus faecalis fsr mutant versus a gelE-sprE mutant in induction of endocarditis. Infect Immun 73:4888-94, 2005.
• Nannini EC, Teng F, Singh KV, Murray BE. Decreased virulence of a gls24 mutant of Enterococcus faecalis 0G1RF in an experimental endocarditis model. Infect Immun. 73:7772-4, 2005.
• Mohamed J, and Murray BE. Lack of correlation of gelatinase production and biofilm formation in a large collection of Enterococcus faecalis isolates. J Clin Microbiol 43:5405-7, 2005.
• Nallapareddy SR, Huang W, Weinstock GM, Murray BE. Molecular characterization of a wide-spread, pathogenic and antibiotic resistance-receptive Enterococcus faecalis lineage and dissemination of its putative pathogenicity island. J Bacteriol 187:6709-18, 2005.
• Raad I, Hanna H, Boktour M, Chaiban G, Hachem, R, Dvorak T, Lewis R, Murray BE. Vancomycin resistant Enterococcus faecium: Catheter colonization, esp gene and decreases susceptibility to antibiotics in biofilm Antimicrob Agents Chemother 49:5046-50, 2005.
• Nallapareddy S, Singh KV, Murray BE. Construction of improved temperature sensitive and mobilizable vectors and their use for constructing mutations in the adhesin encoding acm gene of poorly transformable clinical Enterococcus faecium strains. Appl Environ Microbiol 72:334-45, 2006.
• Mohamed J, Teng F, Nallapreddy, Murray BE. Pleiotrophic effects of the Enterococcus faecalis sagA-like genes, salA and salB, encoding proteins antigenic during human infection, on biofilm formation and binding to collagen I and fibronectin. J Infect Dis 193:231-40, 2006.
• Bourgogne A, Hilsenbeck SG, Dunny GM, and Murray BE. Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: The Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol 188:2875-84, 2006.
• Arias C, Robredo B, Singh KV, Torres C, Panesso Murray BE. Rapid identification of Enterococcus hirae and Enterococcus durans by PCR and detection of a homologue of the E. hirae muramidase-2 gene in E. durans J Clin Microbiol 44:1567-70, 2006.
• Ruiz-Garbajosa P, Bonten M, Robinson A, Top J, Nallapreddy SR, Torres C, Coque T, Conton R, Baquero F, Murray BE, Del Campo R, and Willems R. A multilocus sequence typing scheme for Enterococcus faecalis reveals hospital-adapted genetic complexes in a background of high rates of recombination. J Clin Microbiol 44:2220-8, 2006.
• Kowalski W, Kasper E, Hatton J, Murray BE. Nallapareddy S, Gillespie J. Enterococcus faecalis adhesin, Ace, mediates attachment to particulate dentin . J Endod 32:634-7, 2006.
• Nallapareddy SR, Murray BE. Ligand-signaled upregulation of Enterococcus faecalis ace transcription, a mechanism for modulating host-E. faecalis interaction. Infect Immun 74:4982-9, 2006.
• Mohamed JA, Murray BE. Influence of the fsr locus on biofilm formation be Enterococcus faecalis lacking gelE. J Med Microbiol55:1747-50, 2006.
• Nallapareddy SR, Singh KV, Sillanpaa J, Garsin DA, Hook M, Erlandsen SL, Murray BE. Endocarditis and biofilm-associate pili of Enterococcus faecalis. J Clin Invest 116:2799-807, 2006.
• Tsigrelis C, Singh KV, Coutinho TD, Baddour LM, Murray BE. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J Clin Microbiol 45:631-5,2007.
• Arias CA, Cortes L, Murray BE. Chaining in enterococci revisted: correlation between chain length and gelatinase phenotype, and gelE and fsrB genes among clinical isolates of Enterococcus faecalis. J Med Microbiol 56:286-8,2007.
• Singh KV, Nallapareddy SR, Murray BE. Importance of the endocarditis and biofilm-associated pilus (ebp) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection. J Infect Dis 95:1671-7, 2007.
• Liu Q, Karthe P, Xu Y, Vannakambadi G, Sillanpaa J, Sthanam N, Narayana V.L., Hook M, Murray BE. The Enterococcus faecalis MSCRAMM Ace binds its ligand by the collagen hug model. J Biol Chem 282:19629-37, 2007.
• Nallapareddy SR, Sillanpaa J, Ganesh VK, Hook M, Murray BE. Inhibition of Enterococcus faecium adherence to collagen by antibodies against high-affinity binding subdomains of Acm. Infect Immun. 75:3192-6, 2007.
• Arias CA, Singh KV, Panesso D, Murray BE. Time–kill and synergism studies of ceftobiprole against Enterococcus faecalis including B-lactamase producing and vancomycin-resistant isolates. Antimicrob Agents Chemother. 51:2043-7, 2007.
• Kemp KD, Singh KV, Nallapareddy SR, Murray BE. Relative contributions of Enterococcus faecalis OG1RF sortase encoding genes, srt A and srtC, to biofilm formation and a murine model of urinary tract infection. Infect Immun 75:5399-404, 2007.
• Bourgogne A, Singh KV, Fox KA, Plughoeft KJ, Murray BE, Garsin, DA. EbpR is important for biofilm formation by activating expression of the endocarditis and biofilm-associated pilus operon (ebpABC) of Enterococcus faecalis OG1RF. J Bacteriol 189:6490-3, 2007.
• Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection cause by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44:1536-42, 2007.
• Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 60:594-8, 2007.
• Arias CA, Torres HA, Singh KV, Panesso D, Moore J, Wanger A, Murray BE. Failure of daptomycin monotherapy in the treatment of endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infec Dis 15:1343-6,2007.
• Shelburne SA 3rd, Singh KV, White AC Jr, Byrne L, Carmer A, Austin C, Graviss E, Stager C, Murray BE, Atmar RL. Sequential outbreaks of distinct acinetobacter baumannii strains in a Houston, Texas public teaching hospital. J Clin Microbiol 46:198-205, 2008.   
• Arias CA, Vallejo M, Reyes J, Panesso D, Moreno J, Castaneda E, Villegas MV, Murray BE, Quinn JP.  Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase.  J Clin Microbiol46:892-6, 2008.

Professional Organizations:

• American Society for Microbiology
• American Federation for Clinical Research
• Infectious Diseases Society of America, Fellow
• International Society for Infectious Diseases
• American Society for Clinical Investigation
• The Association of American Physicians

(back to top)

 

Roberto C. Arduino, MD

Professor of Medicine

UT Director of Clinical Research, Thomas Street Clinic

 

Roberto C Arduino, MD graduated from Universidad de Buenos Aires Medical School in 1982, trained in internal medicine from 1982 through 1987, and completed his fellowship in infectious diseases in 1989 in Buenos Aires. He did additional infectious diseases training at the University of Texas Medical School at Houston from 1990-1994.

He has been actively involved in well funded HIV research, first in his native Argentina and now as a Professor in the Division of Infectious Diseases at the University of Texas Medical School at Houston. His current research includes clinical studies in new antiretroviral drugs, treatment strategies, immunomodulators, and research on lymphocyte subpopulations and viral and host genetics. Dr. Arduino is the PISite Leader for the NIH funded CPCRA (Community Program for Clinical Research on AIDS) Clinical Research sSite Houston AIDS Research Team for the AIDS Clinical Trial Group (ATCG) network and the principal investigator for the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).

Peer reviewed publications since 2000:

• Rakita RM, Quan VC, Jacques-Palaz K, Singh KV, Arduino RC, Mee M, and Murray BE. Specific antibody promotes opsonization and PMN-mediated killing of phagocytosis-resistant Enterococcus faecium. FEMS Immunol Med Microbiol 2000;28:291-299.
• Nannini EC, Han X, O'Brien WA, Arduino RC. Genotypic HIV-1 Drug Resistance Testing in Antiretroviral-Naive Subjects in Houston, Texas. J Acquir Immune Defic Syndr 2002;29:317-319.
• Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, Neaton JD; ESPRIT Study Group. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002;23:198-220.
• Kilby MJ, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, and Dusek A. The safety, plasma pharmacokinetics and antiviral activity of subcutaneous T 20, a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002;18:685-693.
• Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A and Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17:691-698.
• Giordano TP, White Jr AC, Sajja P, Graviss EA, Arduino RC, Adu-Oppong A, Lahart CJ, Visnegarwala F. Factors Associated with the Use of Highly Active Antiretroviral Therapy in Patients Newly Entering Care in an Urban Clinic. J Acquir Immune Defic Syndr 2003;32:399-405.
• Tedaldi EM, Hullsiek KH, Malvestutto CD, Arduino RC, Fisher EJ, Gaglio PJ, Jenny-Avital ER, McGowan JP, Perez G, for the Terry Beirn Community Programs for Clinical Research on AIDS. Prevalence and Characteristics of HCV Coinfection in a Human Immunodeficiency Virus Clinical Trials Group: The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 2003;36:1313-1317.
• Vidrine DJ, Amick BC, 3rd, Gritz ER, Arduino RC. Functional Status and Overall Quality of Life in a Multiethnic HIV-Positive Population. AIDS Patient Care STDs 2003;17:187-197.
• Lepetic A, Biscayart C, Seigelchifer M, Arduino R, Stamboulian D. Persistence of immunity and seroprotection four years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine. Vaccine 2003;21:4481-4485.
• Vidrine DJ, Amick BC, 3rd, Gritz ER, Arduino RC. Validity of the Household and Leisure Time Activities Questionnaire (HLTA) in a multiethnic HIV-positive population. AIDS Care 2004;16:187-197.
• Gritz ER, Vidrine DJ, Lazev AB, Amick BC, 3rd, and Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res 2004;6:71-77.
• Lazev AB, Vidrine DJ, Arduino RC, Gritz ER. Increasing access to smoking cessation treatment in a low-income HIV-positive population: The feasibility of using cellular telephones. Nicotine Tob Res 2004;6:281-286.
• Arduino RC, Nannini EC, Rodrigues-Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende M, Emery S, Fosdick L, Neaton J, Tavel J, Davey R, Lane HC. CD4 Cell Response to Three Doses of Subcutaneous Interleukin-2: Meta-analysis of Three Vanguard Studies. Clin Infect Dis 2004;39:115-122.
• Eron JJ, Gulick RM, Bartlett J, Merigan T, Arduino RC, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. Short-Term Safety and Antiretroviral Activity of T-1249, a Second Generation Fusion Inhibitor of HIV. J Infect Dis 2004;189:1075-1083.
• Vidrine DJ, Amick BC, 3rd, Gritz ER, Arduino RC. Assessing a proximal-distal model of quality of life in an HIV-positive population. Qual Life Res 2005; 14:923-933.
• Arduino, RC. CD4 cell count-guided treatment interruption: be smart and wait for more evidence. Clin Infect Dis 2005;40(5):735-7.
• Vidrine DJ, Arduino RC, Lazev AB, Gritz ER. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS 2006; 20(2):253-60.
• Lee S, Arora R, Bull LM, Arduino RC, Garza L, Allan JS, Kimata JT, and Zhou P. A non-neutralizing anti-HIV-1 antibody turns into a broad neutralizing antibody when expressed on the surface of HIV-1-susceptible cells (II): inhibition of HIV-1 captured and transferred by DC-SIGN. AIDS Res Human Retroviruses (In press).
• Pett SL, Wand H, Law MG, Arduino R, Lopez JC, Knysz B, Pereira LC, Pollack S, Reiss P, Tambussi G, ESPRIT Research Group. Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants. HIV Clinical Trials 2006;7:70-85.
• Liu H, Dow EC, Arora R, Kimata JT, Bull LM, Arduino RC, and Rice AP. Integration of HIV-1 during untreated infection occurs preferentially within genes. Journal of Virology 2006;80:7765-8.
• Vidrine DJ, Arduino RC, Gritz ER. Impact of a cell phone intervention on mediating mechanisms of smoking cessation in individuals living with HIV/AIDS. Nicotine Tob Res. 2006 Dec;8 Suppl 1:S103-8.
• The Strategies for Management of Anti-Retroviral Therapy (SMART) Study Group. CD4+ Cell Count–Guided Antiretroviral Treatment. N. Engl. J Med. 2006;355:2283-96.
• Torres JA, Barnett BJ, and Arduino RC. Use of fosamprenavir, a sulfa-containing protease inhibitors, in HIV-infected patients with Glucose 6-Phosphate Dehydrogenase Deficiency. Clinical Infectious Diseases. 2007;44:887-888.
• Lewis DE, Gross KL, Diez MM, Martinez ML, Lukefahr HN, Kozinetz CA, Arduino RC. CD8 apoptosis may be a predictor of T cell number normalization after immune reconstitution in HIV. J Transl Med. 2007 Jan 30;5(1):9.
• Vidrine DJ, Arduino RC, Gritz ER. The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV/AIDS. AIDS Patient Care STDs (in press).
• Torres HA, Bull L, Arduino RC, Barnett BJ. Tongue Hyperpigmentation in a Caucasian Patient Coinfected With HIV and Hepatitis C During Peginterferon Alfa-2b and Ribavirin Therapy. Am J Gastroenterol. 2007 Jun;102(6):1334-1335.
• Fingeret MC, Vidrine DJ, Arduino RC, Gritz ER. The association between body image and smoking cessation among individuals living with HIV/AIDS. Body Image 4 (2007) 201–206.
• Torres HA, Bull L, Arduino RC. Fosamprenavir calcium plus ritonavir for HIV infection. Expert Rev Anti Infect Ther. 2007 Jun;5(3):349-63.
• Torres HA, Barnett BJ, Arduino RC. Alopecia associated with ritonavir-boosted atazanavir therapy. AIDS. 2007 Jun;21(10):1391-1392.

Professional Organizations:

• American Society for Microbiology
• American Academy of HIV Medicine
• Infectious Diseases Society of America

(back to top)

 

Lisa Y. Armitige, MD, PhD

Assistant Professor of Medicine

 

Lisa Y. Armitige, MD, PhD graduated from Rice University, received her MD from the University of Texas Medical School at Houston in 1998 and her PhD in 2002 from the University of Texas Graduate School of Biomedical Sciences. She did a Med/Peds residency at UT Houston from 1998-2002. She was on the faculty in general internal medicine until 2003, when she did her ID fellowship at UT Medical School, Houston from 2003-2005. Her research interest is pathogenesis of Mycobacterium tuberculosis. Current studies in her laboratory include investigations of M. tuberculosis virulence factors and correlates of the bacteria’s behavior with human host response.

Peer Reviewed Publications since 2000:

• Armitige LY, Jagannath C, Wanger AR, and Norris SJ. 2000. Disruption of the genes encoding Antigen 85A and Antigen 85B of Mycobacterium tuberculosis H37Rv: Effect on growth in culture and in macrophages. Infect Immun. 68:767-778.
• Puech V, Guilhot C, Perez E, Tropis M, Armitige LY, Gicquel B, Daffe M. 2002. Evidence for a partial redundancy of the fibronectin-binding proteins for the transfer of mycoloyl residues onto the cell wall arabinogalactan termini of Mycobacterium tuberculosis. Mol Microbiol. 44(4):1109-22.
• Smith K, Armitige LY, Wanger AR. 2003. A review of tuberculosis: reflections on the past, present and future of a global epidemic disease. Expert Rev. Anti-infect. Ther. 1(3), 483-491
• Copenhaver RH, Sepulveda E, Armitige LY , Actor JK, Wanger A, Norris SJ, Hunter, Jr RL, Jagannath C. 2004. A mutant of Mycobacterium tuberculosis H37Rv that lacks the expression of Antigen 85A is attenuated in mice but retains a vaccinogenic potential. Infect Immun. 72(12), 7084-95.
• Singh CR, Moulton RA, Armitige LY, Bidani A, Snuggs M, Dhandayuthapani S, Hunter RL and Jagannath C. 2006. Processing and presentation of a mycobacterial antigen 85B epitope by murine macrophages is denpendent on the phagosomal acquisition of vacuolar proton ATPase and in situ activation of cathepsin D. J Immunol. 177(5): 3250-9.
• Mohamed JA, DuPont HL, Jiang ZD, Belkind-Gerson J, Figueroa JF, Armitige LY, Tsai A, Nair P, Martinez-Sandoval FJ, Guo DC, Hayes P, Okhuysen PCO. 2007. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infec Dis. 44(7)_945-52.

Professional Organizations:

• American Society for Microbiology
• Infectious Diseases Society of America
• American College of Physicians
• American Academy of Pediatrics
  

(back to top)

 

Ben J. Barnett, MD

Associate Professor of Medicine

Associate Medical Director, Harris County Hospital District HIV Services

 

Ben J. Barnett, MD received his medical degree (AOA) from The University of Texas Medical Branch at Galveston. He completed his residency and fellowship at Emory University in Atlanta, Georgia, and was an Epidemic Intelligence Service officer at CDC. Dr. Barnett is an Associate Professor, Department of Internal Medicine, and Division of Infectious Diseases at UT-Houston Medical School. He is Associate Medical Director of HIV Services for the Harris County Hospital District. He is board certified by the American Board of Internal Medicine in Internal Medicine and Infectious Diseases. In addition to being a consummate clinician and teacher, Dr. Barnett also conducts clinical research on HIV/AIDS.

Peer reviewed publications since 2000:

• De la Rosa GR, Barnett BJ, Ericsson CD, Turk JB. Native valve endocarditis due to Bartonella henselae in a middle-aged HIV negative woman. J Clin Microbiol 2001; 39:3417-3419.
• Paphitou NI, Barnett BJ. Solitary Parietal Lobe Histoplasmoma Mimicking a Brain Tumor. Scand J Infect Dis 2002; 34:229-232.
• De la Rosa GR, Barnett BJ. Emphysematous Cholecystitis Secondary to Clostridium perfringens Infection. Infect Med 2002; 19:122-124.
• De la Rosa GR, Kuliev A, Barnett BJ. A case of Strongyloides stercoralis and mesenteric tuberculous infection with acute abdominal pain in an HIV-Positive Patient. Scand J Infect Dis 2002; 34:696-7.
• Amir O, Nguyen VD, Barnett BJ. Acute HIV infection presenting as disseminated gonococcal infection. South Med J 2003; 96:284-286.
• De la Rosa GR, Kuliev A, Barnett BJ. Disseminated tuberculosis with esophageal involvement in an HIV positive patient. Infect Med 2004; 21:133-136.
• Torres HA, Bull LC, Arduino RC, Barnett BJ. Tongue hyperpigmentation in a Caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy. Am J Gastroenterol. 2007 Jun;102(6):1334-1335.
• Torres HA, Barnett BJ, Arduino RC. Use of fosamprenavir, a sulfa containing protease inhibitor, in HIV infected patients with G6PD deficiency. Clin Infect Dis; 2007:44 (15 March) 887-888

As part of a study group:

• Lalezari JP, Henry K, O'Hearn M, et. al, for the TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
• Squires K, Pozniak AL, Pierone G Jr., et al, for the Gilead 907 Study Group. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139:313-20.
• Eron JJ, Gulick RM, Bartlett JA, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis. 2004; 189(6):1075-83.
• Gallant JE, Staszewski S, Pozniak, et al. for the 903 study group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292(2):191-201.
• Gallant JE, DeJesus E, Arribas JR, et al. for the 934 study group. Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. N Engl J Med. 2006;354:251-60.

Professional Organizations:

• American Academy of HIV Medicine
• American Society for Microbiology
• Society for Healthcare Epidemiology of America
• Infectious Diseases Society of America
• American College of Physicians, Fellow
• Texas Infectious Disease Society

(back to top)

 

Tanvir K. Bell, MD

Assistant Professor of Medicine

 

Tanvir Bell, MD received her medical degree from UMNDJ—Robert Wood Johnson Medical School in 1995. She did her Internal Medicine residency at the University of Pittsburgh Medical Center in Pittsburgh, PA and her Infectious Diseases fellowship at Case Western Reserve University in Cleveland, OH. She has been the director of HIV clinics at Allegheny General Hospital in Pittsburgh, PA and University of Texas Medical Branch in Galveston, TX prior to her arrival here in October 2005. She participates in HIV/AIDS clinical trials and a Clostridium difficile clinical trial. She has an interest in issues with HIV infected women and cardiovascular complications of HIV disease.

Peer reviewed publications since 2000:

• Donsky CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. New England Journal of Medicine 2000; 343(26): 1925-32.
• Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, Beinker N, Gripshover BM, Salata RA, McComsey G, Weissman SB, Lederman M. The Changing Spectrum of HIV Mortality: Analysis of 260 Deaths from 1995-1999. Clinical Infectious Diseases 2001; 32: 1487-93.
• Beinker N, Mayers DL, Lange CG, Valdez H, Sitkins J, Lemonnier L, Chowdhry TK, Lederman MM. Brief Report: Genotypic drug resistance and cause of death in HIV-infected persons who died during 1999. Journal of Acquired Immune Deficiency Syndromes 2001; 28(3): 250-53.

Professional Organizations:

• HIV Medicine Association
• American Society for Microbiology
• Infectious Diseases Society of America
  

(back to top)

 

Agathe Bourgogne, PhD

Instructor in Medicine, Research

 

Agathe Bourgogne, PhD received her PhD in Microbiology and Molecular Biology from Université Aix-Marseille II. She is a co-investigator in Dr. Murray’s laboratory. Before joining Dr. Murray’s laboratory she worked on pathogenesis of Bacillus anthracis.

Peer reviewed publications since 2000:

• Bourgogne A, Drysdale M, Hilsenbeck SG, Peterson SN, Koehler TM. Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun. 2003 May;71(5):2736-43
• Drysdale M, Bourgogne A, Hilsenbeck SG, Koehler TM. atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol. 2004 Jan;186(2):307-15.
• Tinsley E, Naqvi A, Bourgogne A, Koehler TM, Khan SA. Isolation of a minireplicon of the virulence plasmid pXO2 of Bacillus anthracis and characterization of the plasmid-encoded RepS replication protein. J Bacteriol. 2004 May;186(9):2717-23.
• Drysdale M, Bourgogne A, Koehler TM. Transcriptional analysis of the Bacillus anthracis capsule regulators. J Bacteriol. 2005 Aug;187(15):5108-14.
• Bourgogne A, Hilsenbeck SG, Dunny GM, Murray BE. Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol 2006; 188:2875-2884.
• Bourgogne A, Singh KV, Fox KA, Pflughoeft KJ, Murray BE, Garsin DA: EbpR is important for biofilm formation by activating expression of the endocarditis and biofilm-associated pilus operon (ebpABC) of Enterococcus faecalis OG1RF. J Bacteriol 2007, 189(17):6490-6493.

Professional Organizations:

• American Society for Microbiology

(back to top)

 

Herbert L. Dupont, MD

Mary W. Kelsey Professor of the Medical Sciences, The University of Texas-Houston Medical School

Chief, Internal Medicine Service, St. Luke's Episcopal Hospital Director, Center for Infectious Diseases, Professor of Epidemiology, The University of Texas-Houston School of Public Health

Clinical Professor, The University of Texas-Houston Medical School

H. Irving Schweppe, Jr., M.D. Chair in Internal Medicine and Vice Chairman, Department of Medicine, Baylor College of Medicine

Clinical Professor, Department of Medicine and Adjunct Professor, Department of Microbiology and Immunology, Baylor College of Medicine

Faculty Member, Graduate Schools of Biomedical Sciences, University of Texas – Houston and Baylor College of Medicine

 

Herbert L. DuPont, MD received his medical degree from Emery University in 1965 and did his internal medicine residency at the University of Minnesota Hospitals followed by an ID fellowship at University of Maryland from 1967-1969, when he was also an EIS officer for the CDC. Dr. DuPont rose rapidly through the ranks. He was appointed Professor of Medicine and Chair of Infectious Diseases and Clinical Microbiology at the University of Texas Medical School at Houston in 1973. He became chief of the internal medicine service at St. Luke’s Episcopal Hospital in 1995. He has been director of the Center for Infectious Diseases at the UT School of Public Health since 2000.

The major focus of Dr. DuPont's research has been to couple laboratory research techniques with application to population studies in the field to study acute infectious diarrhea. Most studies have taken place in countries outside the United States: Mexico, Peru, Egypt, Jamaica, Zambia, Thailand, Kenya and India. A volunteer program was established in Houston to study enteric infectious diseases in humans where the emphasis or research direction has dealt with immunology and pathogenesis of disease. Major foci of the international studies have been on the epidemiology, immunology, clinical features, control, prevention and therapy of selected diarrheal diseases with public health implications. The approaches taken are practical and have clinical applicability. Basic science projects are performed as needed to help fully develop the larger questions suggested by field and laboratory research. Major current interests include studies of the pathogenesis and etiology of travelers’ diarrhea, Clostridium difficile diarrhea and colitis and post-infectious irritable bowel syndrome.

Peer reviewed publications since 2000:

• Paredes, P, Campbell-Forrester, S, Mathewson, JJ, Ashley, D, Thompson, S, Steffen, R, Jiang, Z-D, Svennerholm, A-M, DuPont, HL. Etiology of travelers' diarrhea on a Caribbean island. J Travel Med 2000; 7:15-18.
• White, AC, Jr, Robinson, P, Okhuysen, PC, Lewis, DE, Shahab, I, Lahoti, S, DuPont, HL, Chappell, CL. Interferon-? expression in jejunal biopsies in experimental human Cryptosporidiosis correlates with prior sensitization and control of oocyst excretion. J Infect Dis 2000; 181:701-709.
• Jiang, Z-D, Mathewson, JJ, Ericsson, CD, Svennerholm, A-M, Pulido, C, DuPont, HL. Characterization of enterotoxigenic Escherichia coli strains in patients with travelers' diarrhea acquired in Guadalajara, Mexico, 1992-1997. J Infect Dis 2000; 181:779-782.
• Jiang, Z-D, Ke, S, Palazzini, E, Riopel, L, DuPont, HL. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000; 44:2205-2206.
• Von Sonnenburg, F, Tornieporth, N, Waiyaki, P, Lowe, B, Peruski, LF, Jr, DuPont, HL, Mathewson, JJ, Steffen, R. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 2000; 356:133-134.
• Sutjita, M, Bouckenooghe, AR, Adachi, JA, Jiang, Z-D, Mathewson, JJ, Ericsson, CD, DuPont, HL. Intestinal secretory immunoglobulin A response to enteroaggregative Escherichia coli in travelers with diarrhea. Clin Diag Lab Immunol 2000; 7:501-503.
• Adachi, JA, Jiang, Z-D, Cox, M, Wood, LV, DuPont, HL, Mathewson, JJ. Serum antibody response induced in mice after oral administration of three different antigens of enterotoxigenic Escherichia coli in enteric coated microparticles. J Travel Med 2000; 7:304-308.
• Bouckenooghe, AR, DuPont, HL, Jiang, Z-D, Adachi, J, Mathewson, JJ, Verenker, MP, Rodrigues, S, Steffen, R. Markers of enteric inflammation in enteroaggregative Escherichia coli diarrhea in travelers. Amer J Trop Med Hyg 2000; 62:711-713.
• Dann, SM, Okhuysen, PC, Salameh, BM, DuPont, HL, Chappell, CL. Fecal antibody response to Cryptosporidium parvum in healthy volunteers. Infect Immun 2000; 68:5068-5074.
• Gomi, H, Jiang, Z-D, Adachi, JA, Ashley, D, Lowe, B, Franker, MP, Steffen, R, DuPont, HL. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45:212-216.
• Adachi, JA, Jiang, Z-D, Mathewson, JJ, Verenker, MP, Thompson, S, Martinez-Sandoval, F, Steffen, R, Ericsson, CD, DuPont, HL. Enteroaggregative Escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin Infect Dis 2001; 32:1706-1709.
• Mahmud, MA, Chappell, CL, Hossain, MM, Huang, DB, Habib, M, DuPont, HL. Impact of breast-feeding on Giardia lamblia infections in Bilbeis, Egypt. Am J Trop Med Hyg 2001; 65:257-260
• DuPont, HL, Jiang, Z-D, Ericsson, CD, Adachi, JA, Mathewson, JJ, DuPont, MW, Palazzini, E, Riopel, LM, Ashley, D, Martinez-Sandoval, F. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: A randomized, double-blind clinical trial. Clin Infect Dis 2001; 33:1807-1815.
• Huang, DB, Jiang, Z-D, Ericsson, CD, Adachi, J, DuPont, HL. Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico. Scand J Infect Dis 2001; 33:812-814.
• Mahmud, MA, Hossain, M, Huang, DB, Habib, M, DuPont, HL. Sociodemographic, environmental and clinical risk factors for developing persistent diarrhoea among infants in a rural community of Egypt. J Health Popul Nutr 2001; 19:313-319.
• Mahmud, MA, Marshall, GD, Jr, Hossain, MM, Huang, DB, Habib, M, DuPont, HL. Increased fecal IgE among infants in a rural community of Egypt: an analysis of associated risk factors. J Trop Pediatr 2001; 47:339-344.
• Ericsson, CD, DuPont, HL, Mathewson, JJ. Optimal dosing of ofloxacin with loperamide in the treatment of non-dysenteric travelers' diarrhea. J Travel Med 2001; 8:207-209.
• Jiang, Z-D, Lowe B, Verenker, MP, Ashley, D, Steffen, R, Tornieporth, N, von Sonnenburg, F, Waiyaki, P, DuPont, HL. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002; 185:497-502.
• Greenberg, DE, Jiang, Z-D, Steffen, R, Verenker, MP, DuPont, HL. Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J Infect Dis 2002; 185:944-949.
• Adachi, JA, Mathewson, JJ, Jiang, Z-D, Ericsson, CD, DuPont, HL. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico and in Houston, Texas. Ann Intern Med 2002; 136:884-887.
• Adachi, JA, Ericsson, CD, Jiang, Z-D, DuPont, MW, Pallegar, SR, DuPont, HL. Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis 2002; 185:1681-1683.
• Bouckenooghe, AR, Jiang, Z-D, de la Cabada, FJ, Ericsson, CD, DuPont, HL. Enterotoxigenic Escheri-chia coli as cause of diarrhea among Mexican and US travelers in Mexico. J Travel Med 2002; 9:137-140.
• DiCesare, D, DuPont, HL, Mathewson, JJ, Ashley, D, Martinez-Sandoval, F, Pennington, JE, Porter, SB. A double-blind, randomized, placebo-controlled study of SP303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Amer J Gastroenterol 2002; 97:2585-2588
• Miqdady, MS, Jiang, Z-D, Nataro, JP, DuPont, HL. Detection of enteroaggregative Escherichia coli with formalin-preserved HEp-2 cells. J Clin Micro 2002; 40:3066-3067.
• Jiang, Z-D, Greenberg, D, Nataro, JP, Steffen, R, DuPont, HL. Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers. J Clin Microbiol 2002; 40:4185-4190
• Estrada-Garcia, MT, Jiang, Z-D, Adachi, J, Mathewson, JJ, DuPont, HL. Intestinal immunoglobulin A response to naturally acquired enterotoxigenic Escherichia coli in US travelers to an endemic area of Mexico. J Travel Med 2002; 9:247-250.
• Steffen, R, Sack, DA, Riopel, L, Jiang, Z-D, Stürchler, M, Ericsson, CD, Lowe, B, Waiyaki, P, White, M, DuPont, HL. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98:1073-1078.
• Jiang, Z-D, Okhuysen, PC, Guo, D-C, He R, King, TM, DuPont, HL, Milewicz, DM. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea - polymorphism in interleuken-8 promoter region. J Infect Dis 2003; 188:506-511.
• Hira, SK, Shroff, HJ, Lanjewar, DN, Dholkia YN, Bhatia, VP, DuPont HL. The natural history of adult patients infected with human immunodeficiency virus in Mumbai. Natl Med J India 2003; 16:126-131.
• Huang, DB, Jiang, Z-D, DuPont, HL. Association of virulence factor - positive and - negative enteroaggregative Escherichia coli and occurrence of clinical illness in travelers from the United States to Mexico. Am J Trop Med Hyg 2003; 69:506-508.
• Adachi, JA, Ericsson, CD, Jiang, Z-D, DuPont, MW, Martinez-Sandoval, F, Knirsch, C, DuPont, HL. Azithromycin is comparable to levofloxacin in the treatment of U.S. travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003;37:1165-1171.
• Horvath, LL, Murray, CK, DuPont, HL. Travel health information at commercial travel websites. J Travel Med, 2003; 10:272-279 .
• Infante, RM, Ericsson, CD, Jiang, Z-D, Ke, S, Steffen, R, Riopel, L, Sack, DA, DuPont, HL. Enteroaggregative Escherichia coli diarrhea in travelers: Response to rifaximin therapy. Clin Gastroenterol Hepatol 2004; 2:135-138.
• Huang, DB, Sanchez, AP, Triana, E, Jiang, Z-D, DuPont, HL, Ericsson, CD. United States male students who heavily consume alcohol in Mexico are at greater risk of travelers’ diarrhea than their female counterparts. J Travel Med, 2004; 11:143-147
• Huang, DB, Awasthi, M, Le, B-M, Leve, ME, DuPont, MW, DuPont, HL and Ericsson, CD. The role of diet in the treatment of travelers’ diarrhea: A pilot study. Clin Infect Dis, 2004; 39:468-471.
• Okhuysen, P, Jiang, Z-D, Carlin, L, Forbes, C, DuPont, HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Amer J Gastroenterol 2004;99:1774-1778.
• DuPont, HL, Jiang, Z-D. Influence of rifaximin treatment on susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infec 2004; 10:1009-101
• Steffan, R, Tornieporth, N, Costa Clemens, S-A, Chatterjee, S, Cavalcanti, A-M, Collard, F, DeClercq, N, DuPont, HL, von Sonnenburg, F. Epidemiology of travelers' diarrhea: Details of a global survey. J Travel Med 2004; 11:231-238.
• Huang, DB, DuPont, HL, Jiang, Z-D, Carlin, L, Okhuysen, PC. Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic Escherichia coli. Clin Diagn Lab Immunol 2004; 11:548-551
• DuPont, HL, Jiang, Z-D, Okhuysen, PC, Ericsson, CD, de la Cabada, FJ, Ke, S, DuPont, MW, Martinez-Sandoval, F. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 2005; 142:805-812
• Estrada-Garcia, T, Cerna, JF, Paheco-Gil, L, Velázquez, RF, Ochoa, TJ, Torres, J, DuPont, HL. Drug-resistant diarrheogenic Escherichia coli, Mexico. Emerg Inf. Dis 2005; 11:1306-1308
• Ko, GP, Garcia, C, Jiang, Z-D, Okhuysen, PC, Belkind-Gerson, J, Glass, RI, DuPont, HL. Noroviruses as a cause of traveler’s diarrhea among students from the United States visiting Mexico. J Clin Microbiol 2005;43:6126-6129.
• Jiang, Z-D, DuPont, HL, Garey, K, Price, M, Graham, G, Okhuysen, P, Dao-Tran, T, LaRocco, M. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Amer J Gastroenterol 2006;101:1-5.
• Long, KZ, Estrada-Garcia, T, Rosado, JL, Santos, JI, Haas, M, Firestone, M, Bhagwat, J, Young, C, DuPont, HL, Hertzmark, E, Nanthakumar, NN. The effect of vitamin A supplementation on the intestinal immune response in Mexican children is modified by pathogen infections and diarrhea. J Nutr 2006;136:1365-1370.
• Bundy, JK, Gonzalez, VR, Barnard, BM, Hardy, RJ, DuPont, HL. Gender risk differences for surgical site infections among a primary coronary artery bypass graft surgery cohort: 1995-1998. Amer J Infect Control 2006;34:114-121.
• Ko, GP, Jiang, Z-D, Okhuysen, PC, DuPont, HL. Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to noroviruses. J Med Virol 2006;78:825-828.
• Taylor, DN, Bourgeois, AL, Ericsson CD, Steffen, R, Jiang, Z-D, Halpern, J, Haake, R, DuPont, HL. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Amer J Trop Med Hyg 2006;74:1060-1066.
• Musher, DM, Logan, N, Hamill, RJ, DuPont, HL, Lentnek, A, Gupta, A, Rossignol, J-F. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;15:421-427.
• Garey, KW, Graham, G, Gerard, L, Dao, T, Jiang, Z-D, Price, M, DuPont, HL. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother 2006;40:40:1030-1034.
• Garcia, C, DuPont, HL, Long, KZ, Santos, JI, Ko, G. Asymptomatic norovirus infection in Mexican children. J Clin Micro 2006;44:2997-3000.
• Huang, DB, Nataro, JP, DuPont, HL, Kamat, PP, Mhatre, AD, Okhuysen, PC, Chiang, T. Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta-analysis. Clin Infect Dis, 2006;43:556-563.
• Long, KZ, Santos, JI, Rosado, JL, Lopez-Saucedo, C, Thompson-Bonilla, R, Abonce, M, DuPont, HL, Hertzmark, E, Estrada-Garcia, T. Impact of vitamin A on gastrointestinal pathogen infections and associated diarrheal episodes among children in Mexico City, Mexico. J Infect Dis 2006;194:1217-1225.
• Long, KZ, Santos, JI, Estrada-Garcia, T, Haas, M, Firestone, M, Bhagwat, J, DuPont, HL, Hertzmark, E, Rosado, JL, Nanthakumar, NN. Vitamin A supplementation reduces the monocyte chemoattractant protein-1 intestinal immune response of Mexican children. J Nutr 2006;136:2600-2605.
• Cabada, MM, Maldonado F, Quispe, W, Mozo, K, Serrano, E, Gonzalez, E, Seas, C, Verdonck, K, Echevarria, JI, DuPont, HL, Gotuzzo, E. Risk Factors associated with diarrhea among international visitors to Cuzco, Peru. Am J Top Med Hyg 2006;75:968-972.
• Turner, SM, Chaudhuri, RR, Jiang, Zhi-Dong, DuPont, HL, Gyles, C, Penn, CW, Pallen, MJ, Henderson, IR. Phylogenetic comparisons reveal multiple acquisitions of the toxin genes by enterotoxigenic Escherichia coli strains of different evolutionary lineages. J Clin Microbiol 2006;44:4528-4536.
• Mohamed, JA, Huang, DB, Jiang, Z-D, DuPont, HL, Nataro, JP, Belkind-Gerson, J, Okhuysen, PC. Association of putative enteroaggregative Escherichia coli virulence genes and biofilm production in isolates from U.S. travelers to developing countries. J Clin Microbiol 2006;45:121-126.
• Price, MF, Dao-Tran, T, Garey, KW, Graham, G, Gentry, LO, Dhungana, L, DuPont, HL. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect 2007;65:42-46.
• DuPont, HL, Haake, R, Taylor, DN, Ericsson, CD, Jiang, Z-D, Okhuysen, P, Steffen, R. Rifaximin treatment of pathogen-negative travelers’ diarrhea. J Travel Med 2007;14:16-19.
• Mohamed, JA, DuPont, HL, Jiang, Z-D, Belkind-Gerson, J, Figueroa, JF, Armitige, LY, Tsai, A, Nair, P, Martinez-Sandoval, FJ, Guo, D, Okhuysen, PC. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis 2007;44:945-952.
• Long, KZ, Rosado, JL, DuPont, HL, Hertzmark, E, Santos, JI. Supplementation with vitamin A reduces watery diarrhea and respiratory infections in Mexican children. Brit J Nutr 2007;97:337-343.
• DuPont, HL, Jiang, Z-D, Belkind-Gerson, J, Okhuysen, PC, Ericsson, CD, Ke, S, Huang, DB, DuPont MW, Adachi, JA, de la Cabada, FJ, Taylor, DN, Jaini, S, Martinez Sandoval, F. Treatment of travelers’ diarrhea: Randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatology 2007;5:451-456.
• Ericsson, CD, DuPont, HL, Okhuysen, PC, Jiang, A-D, DuPont, MW. Loperamide plus azithromycin more effectively treats travelers’ diarrhea in Mexico than azithromycin alone. J Travel Med 2007;14:5 312-319.
• Jiang, Z-D, Garey, KW, Price, M, Graham, G, Okhuysen, PC, Dao-Tran, T, LaRocco, M, DuPont, HL. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile associated diarrhea. Clin Gastroenterol Hepatology 2007;5:964-968.
• Long, KZ, Garcia, C, Santos, JI, Rosado, JL, Hertzmark, E, DuPont, HL, Ko, GP. Vitamin A supplementation has divergent effects on Norovirus infections and clinical symptoms among Mexican children. J Infect Dis 2007;196:978-985.
• Huang, DB, Mohamed, JA, Nataro, JP, DuPont, HL, Jiang, Z-D, Okhuysen, PC. Virulence characteristics and the molecular epidemiology of enteroaggregative Escherichia coli isolates from travelers to developing countries. J Med Micro 2007 56:1386-1392.
• Long, KZ, Rosado, JL, Montoya, Y, de Lourdes Dolano, M Hertzmark, E, DuPont, HL, Santos, JI. Effect of vitamin A and zinc supplementation on gastrointestinal parasitic infections among Mexican children. Pediatrics 2007;120:846-855.
• Garcia, C, Samalvides, F, Vidal, M, Gotuzzo, E, DuPont, HL. Epidemiology of Clostridium difficile-associated diarrhea in a Peruvian tertiary care hospital. Amer J Trop Med Hyg 2007;77:802-805.
• DuPont, HL. The growing threat of foodborne bacterial enteropathogens of animal origin. The 15th James H. Steele, DVM Lecture, Clin Infect Dis 2007;45:1353-1961

Professional Organizations:

• American College of Physicians, Fellow
• American Society for Microbiology
• American Society for Clinical Investigation
• Infectious Diseases Society of America, Fellow and Harry A. Feldman Presidential Award
• International Society of Travel Medicine, (Past and Founding President)
• Houston Infectious Diseases Society
• American Clinical and Climatological Association (Past President)
• American Federation for Clinical Research
• American Epidemiological Society
• American Academy of Microbiology, Fellow
• Association of American Physicians
• International Society for Infectious Diseases
• Southern Society for Clinical Investigation

(back to top)

 

Charles D. Ericsson, MD

Professor of Medicine

Head, Clinical Infectious Diseases

Vice Director, Infectious Disease Fellowship Program

Director, Travel Medicine Clinic

Administrative Director, Clinical Infectious Diseases Elective 4th year students

Co-Director, 3rd-4th Year Medical Student Affairs in Medicine

 

Charles D. Ericsson, MD received his medical degree from Harvard Medical School in Boston, Massachusetts. After residency training at the University of Minnesota hospitals, he completed a fellowship in infectious diseases at UT- Medical School at Houston. Dr. Ericsson is a Professor of Medicine at UT-Houston Medical School and Head, Clinical Infectious Diseases, Department of Internal Medicine, Director of the Travel Medicine Clinic and Vice Director of the Infectious Diseases Fellowship program at UT Medical School at Houston. He is board certified by the American Board of Internal Medicine.

Dr. Ericsson has heavy clinical infectious diseases consultative and teaching duties. He has received several awards for his teaching. He is founding Editor-in-Chief of The Journal of Travel Medicine and Past President of the International Society of Travel Medicine. He is also Travel Medicine Section Editor of Clinical Infectious Diseases. His current research interests include travelers’ diarrhea and travel medicine; he has journeyed each summer to Guadalajara Mexico to conduct clinical trials in travelers’ diarrhea since 1975. He is also heavily involved in hospital infection control and antibiotic approval programs.

Peer reviewed publications since 2000.

• Sutjita M, Bouckenooge A, Adachi JA, Jiang Z-D, Ericsson CD, DuPont HL. Intestinal secretory IgA response to enteroaggregative Escherichia coli in travelers. Clin Diag Lab Immunol 7:501-3, 2000.
• Adachi JA, D'Alessio FR, Ericsson CD. Reactive arthritis associated with typhoid vaccination in travelers: report of two cases with negative HLA-B27. J Travel Med. 7:35-6, 2000.
• Jiang Z-D, Mathewson JJ, Ericsson CD, Svennerholm A-M, Pulido C, DuPont HL. Characterization of enterotoxigenic Escherichia coli (ETEC) strains in patients with travelers’ diarrhea acquired in Guadalajara, Mexico, 1992 through 1997. J Infect Dis 181:779-82, 2000.
• Adachi J, Ostrosky-Zeichner L, DuPont HL, Ericsson CD. Empirical antimicrobial therapy for travelers’ diarrhea. Clin Infec Dis 31:1079-83, 2000.
• Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infec Dis. 33, 375-379, 2001
• DuPont HL, Jiang Z-D, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, Palazzini E, Riopel LM, Ashley D, Martinez-Sandoval F. Rifaximin versus ciprofloxacin for the treatment of travelers’ diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 33:1807-15, 2001
• Adachi JA, Jiang, Z-D, Mathewson JJ, Mangala P, Verenkar MP, Thompson S, Martinez-Sandoval F, Steffen R, Ericsson CD, DuPont HL. Enteroaggregative Escherichia coli as a major etiologic agent in travelers’ diarrhea in three regions of the world. Clin Infect Dis 32:1706-9, 2001
• Ericsson CD, DuPont HL, Mathewson JJ: Optimal dosing of ofloxacin with loperamide in the treatment of non-dysenteric travelers’ diarrhea. J Travel Med 8:19-25, 2001
• De La Rosa GR, Barnett BJ, Ericsson CD, Turk JB. Native valve endocarditis due to Bartonella henselae in a middle-aged Human Immunodeficiency Virus-negative woman. J Clin Microbiol 39:3417-19, 2001.
• Huang DB, Jiang ZD, Ericsson CD, Adachi J, Dupont HL. Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico. Scand J Infect Dis 33:812-4, 2001.
• Adachi JA, Mathewson JJ, Jiang ZD, Ericsson CD, Dupont HL. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico and Houston, Texas. Ann Intern Med 136:884—887, 2002.
• Bouckenooghe AR, Jiang ZD, De La Cabada FJ, Ericsson CD, DuPont HL. Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. J Travel Med 9:137-40, 2002.
• Adachi JA, Ericsson CD, Jiang ZD, DuPont MW, Pallegar SR, DuPont HL. Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis 185:1681-3, 2002.
• Marcolini J, Nguyen M, Ericsson CD. Klebsiella pneumoniae brain abscess in a Taiwanese adult. J Infect 44: 205-206, 2002;
• Ericsson, CD. Travelers with pre-existing medical conditions. International J Antimicrob Agents 2003; 21: 181-88.
• Ericsson, CD. Travelers’ diarrhea. International J Antimicrob Agents 2003; 21: 116-24.
• Steffen, R, Sack, DA, Riopel, L, Jiang Z-D, Stürchler, M, Ericsson, CD, Lowe, B, Waiyaki, P, White, M, DuPont, HL. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003: 98:1073-78.
• Adachi, JA, Ericsson, CD, Jiang, Z-D, DuPont, MW, Martinez-Sandoval, F, Knirsch, C, DuPont, HL. Azithromycin is Comparable to Levofloxacin in the Treatment of U.S. Travelers with Acute Diarrhea Acquired in Mexico. CID 37:1165-71, 2003
• Infante RM, , Ericsson CD, Jiang Z-D, Ke S, Steffen R, Riopel L, Sack DA, DuPont HL. Enteroaggregative Escherichia coli (EAEC) Diarrhea in Travelers: Response to Rifaximin Therapy. Clin Gastroenterol Hepatology 2004; 2:135-8.
• Huang DB, Sanchez AP, Triana E, Jiang Z-D, DuPont HL, Ericsson CD. US male students who heavily consume alcohol in Mexico are at greater risk of travelers’ diarrhea than their female counterparts. J Travel Med 2004; 11:143-147.
• Huang DB, Awasthi M, Le J, Leve M, DuPont MW, DuPont HL, Ericsson CD. The role of diet in the treatment of travelers’ diarrhea: a pilot study. CID 2004; 39:468-71.
• Mohr JF, Ericsson CD, Hall AC, Ostrosky-Zeichner L. Amphotericin B Overdose: A Fatal Case of Lipid and Non-Lipid Formulation Mix-Up. Pharmacotherapy 2005; 25: 426-8.
• Ericsson CD, DuPont HL. Rifaximin in the treatment of infectious diarrhea. Chemother 2005; 51(suppl 1):73-80.
• DuPont HL, Jiang Z-D, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. Prevention of travelers’ diarrhea with rifaximin, a non-absorbed antibiotic. Annals Intern Med 2005; 142: 805-12.
• DuPont HL, Jiang Z-D, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. Antibacterial chemoprophylaxis in the prevention of travelers’ diarrhea. Clin Infect Dis 2005; 41:S
• Ericsson CD. Non antimicrobial agents in treatment and prevention of travelers’ diarrhea. Clin Infec Dis 2005; 41:S557-63.
• Ericsson CD. Safety and tolerability of the antibacterial rifaximin in the treatment of travelers’ diarrhea. Drug Safety 2006; 29:201-7.
• Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang Z-D, Halpern J, Haake R, Kamm AR, DuPont HL and the Rifaximin Study Group. A Randomized, Double-Blind, Multicenter Study of Rifaximin Compared with Placebo and with Ciprofloxacin in the Treatment of Travelers’ Diarrhea. (Am J Trop Med Hygiene 2006; 74:1060-66.
• Hill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE, DuPont HL, Bia FJ, Fischer PR, Ryan ET. Guidelines for the Practice of Travel Medicine. Clin Infec Dis 2006; 43:1499-1539.
• DuPont HL, Haake R, Taylor DN, Ericsson CD, Jiang Z-D, Okhuysen P, Steffen R. Rifaximin treatment of pathogen-negative travelers’ diarrhea. J Travel Med 2007; 14:16-19.
• Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007; 5:451-6
• Ericsson CD, DuPont HL, Okhuysen PC, Jiang Z-D, de la Cabada FJ, DuPont MW, Martinez-Sandoval F. Loperamide plus azithromycin more effectively treats travelers’ diarrhea in Mexico than azithromycin alone. J Travel Med 2007; 14:312-319.
• Meraz IM, Jiang Z-D, Bourgeois AL, Steffen R, Ajami NJ, Koo HL, Ericsson CD, Taylor DN, DuPont HL. Etiology of pathogen negative travelers’ diarrhea - a PCR-based study of selected enteropathogens. (in preparation)

Professional Organizations:

• American College of Physicians, Fellow
• American Society for Microbiology
• American Society of Tropical Medicine and Hygiene
• Infectious Diseases Society of America, Fellow
• International Society of Travel Medicine, Past President
• Founding Editor, Journal of Travel Medicine
• Wilderness Medicine Society
• Houston Infectious Diseases Society

(back to top)

 

Sreedhar R. Nallapareddy, PhD

Assistant Professor, Internal Medicine Research

 

Sreedhar R. Nallapareddy, PhD received a PhD in genetics in 1998 from the University of Madras, Madras, India. Dr. Nallapareddy is co-investigator in Dr. Murray’s laboratory.

 

Peer reviewed publications since 2000:

• Nallapareddy, S.R., Singh, K.V., Duh, R.W., Weinstock, G.M., and Murray, B.E.: Diversity of ace, a gene encoding a microbial surface component recognizing adhesive matrix molecules, from different strains of Enterococcus faecalis and evidence for production of ace during human infections. Infect Immun. 68:5210-5217, 2000
• Nallapareddy, S.R., Qin, X., Weinstock, G.M., Hook, M., and Murray, B.E.: An Enterococcus faecalis OG1RF adhesin, Ace, mediate attachment to extracellular matrix proteins collagen type IV and laminin as well as collagen type I. Infect Immun. 68:5218-5224, 2000.
• Nallapareddy, S.R., Duh, R.W., Singh, K.V., and Murray, B.E.: Molecular typing of selected Enterococcus faecalis isolates: Pilot study using multilocus sequence typing and pulsed-field gel electrophoresis. J Clin Microbiol. 40: 868-876. 2002.
• Gilmore, M.S., Coburn, P.S., Nallapareddy, S.R., and Murray, B.E.: Enterococcal Virulence. In: The Enterococci: Pathogenesis, Molecular Biology and Antibiotic Resistance, Eds. M. S. Gilmore, D. Clewell, P. Courvalin, G. M. Dunny, B. E .Murray, and L. Rice. ASM Press, Washington, DC, 2002.
• Hubble, T.S., Hatton, J.F., Nallapareddy, S.R., Murray, B.E., and Gillespie, M.J.: Influence of Enterococcus faecalis proteases and the collagen-binding protein, Ace, on adhesion to dentin. Oral Microbiol and Immunol.18:121-126, 2003.
• Nallapareddy, S.R., Weinstock, G.M., and Murray, B.E.: Clinical isolates of Enterococcus faecium exhibit strain-specific collagen binding mediated by Acm, a new member of the MSCRAMM family. Mol Microbiol. 47:1733-1747. 2003.
• Nallapareddy, S.R., Wenxiang, H., Weinstock, G.M., and Murray, B.E.: Molecular characterization of a widespread, pathogenic, and antibiotic resistance-receptive Enterococcus faecalis lineage and dissemination of its putative pathogenicity island. J Bacteriol. 187: 5709-5718. 2005.
• Rice, L.B., Carias, L., Rudin, S., Vael, C., Goossens, H., Konstabel, C., Klare, I., Nallapareddy, S.R., Huang, W., and Murray, B.E.: A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis. 187:508-512, 2003.
• Sillanpaa, J., Xu, Y., Nallapareddy, S.R., Murray, B.E., and Hook, M.: A family of putative MSCRAMMs from Enterococcus faecalis. Microbiology. 150:2069-2078, 2004.
• Mohamed, J. A., Huang, W., Nallapareddy, S.R., Teng, F., Murray B.E.: Influence of origin of isolates, especially endocarditis isolates, and various genes on biofilm formation by Enterococcus faecalis. Infection and Immunity 72:3658-63, 2004.
• Mohamed, J.A., Teng, F., Nallapareddy S.R., Murray, B.E.: Pleiotrophic effects of 2 Enterococcus faecalis sagA-like genes, salA and salB, which encode proteins that are antigenic during human infection, on biofilm formation and binding to collagen type I and fibronectin. J Infect Dis 193:231-240, 2006
• Nallapareddy, S.R., Singh, K.V., and Murray. B.E: Construction of improved temperature-sensitive and mobilizable vectors and their use for constructing mutations in the adhesin encoding acm gene of poorly transformable clinical Enterococcus faecium Strains. Appl Environ Microbiol. 72:334-345, 2006
• Singh K.V., Nallapareddy, S.R., Nannini E.C., and Murray B.E.: Fsr-independent production of protease(s) may explain the lack of attenuation of an Enterococcus faecalis fsr mutant versus a gelE-sprE mutant in induction of endocarditis. Infect Immun. 73:4888-4894, 2005.
• Kowalski, W.J., Kasper, E.L., Hatton, J.F., Murray, B.E., Nallapareddy, S.R., and Gillespie, M.J.: Enterococcus faecalis adhesin, ace, mediates attachment to particulate dentin. J Endod 32:634-637, 2006.
• Ruiz-Garbajosa, P., Bonten, M.J., Robinson, D.A., Top, J., Nallapareddy, S.R., Torres, C., Coque, T.M., Canton, R., Baquero, F., Murray, B.E., et al.: Multilocus sequence typing scheme for Enterococcus faecalis reveals hospital-adapted genetic complexes in a background of high rates of recombination. J Clin Microbiol 44:2220-2228,2006
• Nallapareddy, S.R., and Murray, B.E.: Ligand-Signaled Upregulation of Enterococcus faecalis ace Transcription, a Mechanism for Modulating Host-E. faecalis Interaction. Infect Immun, 74:4982-89, 2006.
• Nallapareddy, S.R., Singh, K.V., Sillanpaa, J., Garsin, D.A., Hook, M., Erlandsen, S.L., and Murray, B.E.: Endocarditis and biofilm-associated pili of Enterococcus faecalis. J Clin Invest 116:2799-807, 2006.
• Nallapareddy, S.R., Sillanpaa, J., Ganesh, V.K., Hook, M., and Murray B.E.: Inhibition of Enterococcus faecium adherence to collagen by antibodies against high-affinity binding subdomains of Acm. Infect Immun 75:3192-6, 2007.
• Singh, K.V., Nallapareddy, S.R., and Murray B.E.: Importance of the ebp (endocarditis- and biofilm-associated pilus) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection. J Infect Dis 195:1671-7, 2007.
• Kemp, K.D., Singh, K.V., Nallapareddy, S.R., and Murray B.E.: Relative contributions of Enterococcus faecalis OG1RF sortase-encoding genes, srtA and bps (srtC), to biofilm formation and a murine model of urinary tract infection. Infect Immun 75:5399-404, 2007.
• Nallapareddy, S.R., and Murray B.E.: Role of Serum, a biological cue, in adherence of Enterococcus faecalis to extracellular matrix proteins, collagen, fibrinogen, and fibronectin, J Infect Dis, In Press. 2008

Professional Organizations:

• American Society for Microbiology
  

(back to top)

 

Pablo C. Okhuysen, MD

Professor of Medicine

Director, Clinical Research Unit

Past Director, Infectious Disease Fellowship Program

 

Pablo C. Okhuysen, MD received his medical school training at the Universidad Autonoma de Guadalajara. He performed his internship at Cook County Hospital in Chicago and completed his residency at the University of Texas Medical School at Houston, where he stayed on to do a fellowship in infectious diseases and eventually joined the faculty. He quickly rose to the rank of Professor and has previously served as the Director of the ID fellowship program at UT Medical School.

His successful research program is NIH funded and focuses on HIV and enteric diseases. Dr. Okhuysen works on the pathogenicity, epidemiology and host response to Cryptosporidium parvum. In a related project he aims to identify host genetic polymorphisms that are associated with susceptibility to agents of infectious diarrhea, emphasizing infections due to Enterotoxigenic E. coli, enteroaggregative E. coli and Cryptosporidium. He is now Director of the Clinical Research Unit and is co-Director of the Center for Clinical and Translational Sciences. The goals of the CRU are to provide an environment for the study of normal and abnormal body function; investigate the cause, progression, prevention, control and care of human disease; furnish an optimal setting for controlled clinical investigations by UTHSC scientists and serve as an environment for training health professionals in clinical research.

Dr. Okhuysen is principal investigator for the UTHSC component of the NIH funded vaccine trials and evaluation unit (VTEU) at Baylor College of Medicine. VTEU related studies include volunteer challenge studies with enteroaggregative E. coli and seroepidemiologic studies on Enterotoxigenic E. coli.

Selected Peer Reviewed Publications since 2000:

• White AC, Robinson P, Okhuysen PC, Lewis DE, Shahab I, Lahoti S, DuPont HL, Chappell CL. Interferon-gamma Expression in jejunal biopsies in experimental human cryptosporidiosis correlates with prior sensitization and control of oocyst excretion. J Infect Dis. 2000 Feb; 181(2): 701-709.
• Robinson P, Okhuysen PC, Chappell CL, Lewis DE, Shahab I, Lahoti S, White, Jr., AC.TGF-?1 is expressed in the jejunum after experimental human Cryptosporidium parvum infection. Infect Immun.2000;68: 5405-5407.
• Dann MS, Okhuysen PC, DuPont HL, Chappell CL, Fecal antibody response to Cryptosporidium parvum in healthy volunteers. Infect and Immun. 2000;68:5068-5074.
• Robinson P, Okhuysen PC, Chappell CL., Lewis DE., Shahab I, Janecki A, White, AC, Jr. Expression of tumor necrosis factor alpha and interleukin ß1in jejuna of volunteers after experimental challenge with Cryptosporidium parvum correlates with exposure but not with symptoms. Infect. Immun. 2001 69: 1172-1174.
• Okhuysen PC, Robinson P, Nguyen MT, Nannini E, Lewis D, Lahoti S, Chappell C, White, AC. The jejunal cytokine response in patients with AIDS associated cryptosporidiosis during immune reconstitution. AIDS, 15:802-804, 2001.
• Okhuysen PC. Traveler’s Diarrhea due to Intestinal Protozoa. Clin Inf Dis . 33:110-114, 2001.
• Robinson, P, Okhuysen PC, Chappell, CL, Lewis DE, Shahab I, Lahoti S, and White AC Jr. Expression of IL-15 and IL4 in INF-?-Independent control of experimental human Cryptosporidium parvum Infection. Cytokine 7:39-46, 2001.
• Padda R, Tsai A, Chappell, CL, Okhuysen PC. Molecular cloning and analysis of the Crytosporidium pavum aminopeptidase N Gene. Int. J. Parasitol. 2002, 32:187-197.
• Okhuysen, PC, CL Chappell, Cryptosporidium virulence determinants – are we there yet? Int. J. Parasitol. 32:517-525, 2002.
• Okhuysen, PC, Rich SM, Chappell CL, Grimes KA, Widmer G, Feng X, Tzipori S. Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and gamma Interferon-? knock out mce. J. Infect Dis. 2002, 185:1320-1325.
• Teunis PF, Chappell CL and Okhuysen PC. Cryptosporidium dose-response studies: variation between hosts. Risk Analysis. 2002:3, 475-485.
• Teunis PF, Chappell CL Okhuysen PC. Cryptosporidium dose response studies: variation between isolates. Risk Analysis. 2002:1, 175-183.
• Millership JJ, Chappell C, Okhuysen PC, Snowden KF.Characterization of aminopeptidase activity from three species of microsporidia: Encephalitozoon cuniculi, Encephalitozoon hellem,and Vittaforma corneae. J Parasitol. 2002:88:843-8
• Nannini EC, Okhuysen PC. HIV1 and the gut in the era of highly active antiretroviral therapy. Curr. Gastroenteral Rep. 2002, 4:392-298.
• Alcantara CA, Steiner T, Barret L, Guerrant RL, Yang CH, Lima A, Chappell CL, Okhuysen PC, White AC. IL-8, TNF-alpha and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. Am J Trop Med Hyg. 2003:3; 325-328.
• Jiang ZD, Okhuysen PC, Guo DC, He R, King TM, DuPont HL, Milewicz DM. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003;188:506-11.
• Robinson P, Okhuysen PC, Chappell CL, Weinstock JV, Lewis DE, Actor JK, White AC, Jr. Substance P expression correlates with severity of diarrhea in cryptosporidiosis. J Infect Dis 2003;188:290-6.
• White AC, Jr., Robinson P, Okhuysen PC. Human studies provide insight into the pathogenesis, immunology, and treatment of cryptosporidiosis. Clin Infect Dis 2003;37:989; author reply 989-90.
• Huang DB, Okhuysen PC, Jiang ZD, DuPont HL. Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol 2004;99:383-9.
• Okhuysen PC, Rogers GA, Crisanti A, Spano F, Huang DB, Chappell CL, Tzipori S. Antibody response of healthy adults to recombinant thrombospondin-related adhesive protein of Cryptosporidium 1 after experimental exposure to Cryptosporidium oocysts. Clin Diagn Lab Immunol 2004;11:235-8.
• Roberts JC, Singh KV, Okhuysen PC, Murray BE. Molecular epidemiology of the fsr locus and of gelatinase production among different subsets of Enterococcus faecalis isolates. J Clin Microbiol 2004;42:2317-20.
• Huang DB, DuPont HL, Jiang ZD, Carlin L, Okhuysen PC. Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic Escherichia coli. Clin Diagn Lab Immunol 2004;11:548-51.
• Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J. Gastroenterol. 2004 99:1774-8.
• Kjos SA, Jenkins M, Okhuysen PC, Chappell CL. Evaluation of Recombinant Oocyst Protein CP41 for Detection of Cryptosporidium-Specific Antibodies. Clin Diagn Lab Immunol. 2005;12:268-72.
• Huang DB, Chappell C, Okhuysen PC. Cryptosporidiosis in children. Semin Pediatr Infect Dis. 2004 15(4):253-9.
• Kjos SA, Jenkins M, Okhuysen PC, Chappell CL. Evaluation of Recombinant Oocyst Protein CP41 for Detection of Cryptosporidium-Specific Antibodies.Clin Diagn Lab Immunol. 2005. 12:268-72.
• DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-812.
• Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E and Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303-9
• Okhuysen PC, Chappell CL, Lewis DE, Robinson P and White AC, Jr. Treatment of chronic cryptosporidiosis in AIDS with rIL-12 induces an immune response associated with improvement but severe side-effects. AIDS 2005;19:1333-4.
• Ko G, Garcia C, Jiang ZD, Okhuysen PC, Belkind-Gerson J, Glass RI, DuPont HL. Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol. 2005;43:6126-9.
• Ko G, Jiang ZD, Okhuysen PC, Dupont HL. Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses. J Med Virol 2006;78:825-8.
• Jiang ZD, Dupont HL, Garey K, Price, M, Graham, G, Okhuysen, P, Dao-Tran, T, Larocco, M. A Common Polymorphism in the Interleukin 8 Gene Promoter Is Associated with Clostridium difficile Diarrhea. Am J Gastroenterol 2006:101;1112-1116
• Huang DB, Mohanty A, Dupont HL, Okhuysen PC, Chiang T. A review of an emerging enteric pathogen: enteroaggregative Escherichia coli. J Med Microbiol. 2006;55:1303-11.
• Huang DB, Nataro JP, DuPont HL, Kamat PP, Mhatre AD, Okhuysen PC, Chiang T. Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta-analysis. Clin Infect Dis. 2006;43:556-63.
• Chappell CL, Okhuysen PC, Langer-Curry R, et al. Cryptosporidium hominis: experimental challenge of healthy adults. Am J Trop Med Hyg 2006;75:851-7
• The strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ Count-Guided Interruption of Antiretroviral Treatment. N. Engl J Med 2006:355;2283-96
• Wang HC, Dann SM, Okhuysen PC, Lewis DE, Chappell CL, Adler DG, White AC, Jr. High levels of CXCL10 are produced by intestinal epithelial cells in AIDS patients with active cryptosporidiosis but not after reconstitution of immunity. Infect Immun. 2007;75:481-7.
• Mohamed JA, Huang DB, Jiang ZD, Dupont HL, Nataro JP, Belkind-Gerson J, Okhuysen PC. Association of putative enteroaggregative Escherichia coli virulence genes and biofilm production in isolates from travelers to developing countries. J Clin Microbiol. 2007;45:121-126.
• Mohamed JA, Dupont HL, Jiang ZD, Belkind-Gerson J, Flores-Figueroa JF, Armitige LY, Nair P, Tsai A, Martinez-Sandoval FJ, Guo DC, Okhuysen PC A novel single nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis. 2007:44:945-52
• Aguirre-Garcia MM, Okhuysen PC Cryptosporidium parvum: identification and characterization of an acid phosphatase. Parasitol Res. 2007 101;85-9
• DuPont HL, Haake R, Taylor DN, Ericsson CD, Jiang ZD, Okhuysen PC, Steffen R. Rifaximin treatment of pathogen-negative travelers' diarrhea. J Travel Med. Jan-Feb 2007;14:16-9.
• The ESPRIT Research Group. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>/=300 cells/muL who were assigned to 7.5 MIU interleukin-2. HIV Med. 2007:8:112-23
• Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol. 2007:5:451-6.
• Jiang ZD, Garey KW, Price M, Graham G, Okhuysen P, Dao-Tran T, Larocco M, Dupont HL. Association of Interleukin-8 Polymorphism and Immunoglobulin G Anti-Toxin A in Patients with Clostridium difficile-Associated Diarrhea, Clin Gastroenterol Hepatol. 2007;5:964-8
• Ericsson CD, DuPont HL, Okhuysen PC, Jiang ZD, DuPont MW. Loperamide Plus Azithromycin More Effectively Treats Travelers’ Diarrhea in Mexico than Azithromycin Alone. J Travel Med. 2007 14;312–319
• Huang DB, Mohamed JA, Nataro JP, DuPont HL, Jiang ZD, Okhuysen PC. Virulence Characteristics and the Molecular Epidemiology of Enteroaggregative Escherichia coli Isolates from Travelers to Developing Countries. J Medical Microbiology 2007; 56: 1386-92.
• Flores J, DuPont HL, Jiang ZD, Belkind-Gerson J, Mohamed JA, Carlin LG, Padda R, Paredes, Martinez-Sandoval F, Villa NA, Okhuysen PC. Enterotoxigenic Escherichia coli Heat-Labile Toxin Seroconversion in US travelers to Mexico. Journal of Travel Medicine 2007; (In press).

Professional Organizations:

• AOA Medical Honors Society
• Houston Chapter American College of Physicians, Fellow
• American Society for Microbiology
• American Society of Tropical Medicine and Hygiene
• Infectious Diseases Society of America, Fellow
• Houston Infectious Diseases Society, president 08-09

(back to top)

 

Luis Ostrosky-Zeichner, M.D., FACP, FIDSA

Associate Professor of Medicine

Associate Director, Infectious Diseases Fellowship

Director, Laboratory of Mycology Research

Medical Director for Epidemiology, Memorial Hermann Hospital Texas Medical Center

 

Dr. Ostrosky-Zeichner obtained his medical degree from Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency at Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and his infectious diseases fellowship at the University of Texas Medical School at Houston and MD Anderson Cancer Center combined fellowship program. He has advanced training and experience in medical mycology and hospital epidemiology.

He is currently an associate professor of medicine and epidemiology, and the director of the Laboratory of Mycology Research, at the Division of Infectious Diseases of the University of Texas Medical School at Houston. He also serves as the associate fellowship program director and medical director for epidemiology for Memorial Hermann Texas Medical Center. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is an editorial board member of prestigious scientific journals such as Antimicrobial Agents and Chemotherapy, Critical Care Medicine, and Journal of Clinical Microbiology.

Dr. Ostrosky-Zeichner actively pursues translational and clinical research in medical mycology and hospital epidemiology, having over 100 publications in both fields. His areas of expertise include: antifungal susceptibility testing, fungal serologies, PK/PD of antifungals, in vivo models of human mycoses, immunology, and clinical trials in prophylaxis and treatment of fungal infections, as well as hospital epidemiology and infection control.

Key publications:

• Ostrosky-Zeichner L, Soto-Hernadez JL, Angeles-Morales V, Teixeira F, Nava-Ruiz C, Rios C, Solis F, Sotelo J. Effects of Pentoxifylline or Dexamethasone in Combination with Amphotericin B in Experimental Murine Cerebral Cryptococcosis: Evidence of Neuroexcitatory Pathogenic Mechanisms. Antimicrob Agents Chemother 1996; 40:1194-7.
• Ponce de León S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet 1999; 353:1244.
• Ostrosky-Zeichner L, Baez-Martinez R, Rangel-Frausto MS, Ponce de Leon S. Epidemiology of Nosocomial Outbreaks: 14-Year Experience at a Tertiary-Care Center. Infect Control Hosp Epidemiol2000;21:527-9.
• Adachi J, Ostrosky-Zeichner L, Dupont HL, Ericsson CD. Empirical Antimicrobial Therapy for Traveler’s Diarrhea. Clin Inf Dis 2000; 31:1079-83.
• Ostrosky-Zeichner L, Bazemore S, Paetznick VL, Rodriguez JR, Chen E, Wallace T, Cossum P, Rex JH. Differential Antifungal Activity of Isomeric Forms of Nystatin. Antimicrob Agents Chemother 2001; 45:2781-6
• Ostrosky-Zeichner L, Rex JH, Bennett JE, Kullberg BJ. Deeply Invasive Candidiasis. Inf Dis Clin N Am 2002; 16:821-35.
• Ostrosky-Zeichner L, Marr KA, Rex, JH, Cohen SH. Reviews of Anti-infectives: Amphotericin B: Time for a New “Gold Standard”. Clin Inf Dis 2003; 37:415-25.
• Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. for the National Institute of Allergy and Infectious Diseases Mycoses Study Group Candidiasis Subproject. Comparative Antifungal Susceptibility Survey of 2,000 Bloodstream Isolates of Candida spp. from the United States. Antimicrob Agents Chemother 2003; 47:3149-54.
• Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, and Rex JR. Voriconazole Salvage Treatment of Invasive Candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22:651-5.
• Odabasi Z,Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cut-off Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clinical Infect Dis 2004; 39:199-205.
• Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination Antifungal Therapy. Antimicrob Agents Chemother 2004; 48:693-715.
• Ostrosky-Zeichner L. Prophylaxis and Treatment of Invasive Candidiasis in the Intensive Care Setting. Eur J Clin Microbiol Infect Dis 2004; 23:739-44.
• Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005; 40 Suppl 6:S409-13.
• Cocanour CS, Ostrosky-Zeichner L, Peninger M, Garbade D, Tidemann T, Domonoske BD, Li T, Allen SJ, Luther KM. Cost of a Ventilator-Associated Pneumonia in a Shock Trauma Intensive Care Unit. Surg Infect (Larchmt) 2005; 6:65-72.
• Mohr JF, Peninger M, Ostrosky-Zeichner L. Infection Control in the ICU. J Pharm Practice 2005;18:84-90.
• Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: An approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43:235-43.
• Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH. Multicenter Clinical Evaluation of the (1→ 3) β-D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans. Clin Infect Dis 2005; 41:654-9.
• Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller M, Rinaldi M, Schell W, Walsh T. Quality Control and Reference Guidelines for CLSI Broth Microdilution Susceptibility Method (M38-A Document) for Amphotericin B, Itraconazole, Posaconazole, and Voriconazole. J Clin Microbiol 2005;43:5243-6.
• Johnson MD, Kleinberg M, Danzinger L, Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions. Expert Op Pharmacother 2005; 6:2617-32.
• Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24:654-61.
• Ostrosky-Zeichner L, Pappas PG. Invasive Candidiasis in the ICU. Crit Care Med 2006;34:857-63.
• Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-6.
• Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27.
• Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. Clin Infect Dis 2007; 45:883-93.

Professional Organizations:

• Fellow of the American College of Physicians
• Fellow of the Infectious Diseases Society of America
• Society of Healthcare Epidemiology of America
• Mycoses Study Group
• American Society for Microbiology
• Houston Infectious Diseases Society
• HIV Medicine Association

(back to top)

 

Kavindra Vikram Singh, Ph.D.

ASSISTANT PROFESSOR OF INTERNAL MEDICINE RESEARCH

 

Kavindra Vikram Singh, Ph.D. received his PhD in 1981 from Sagar University, Sagar, India. He is a co-investigator in Dr. Murray’s laboratory. He is involved in teaching to graduate students and post doctoral M.D. fellows.

Peer reviewed publications since 2000:

• Shelburne SA 3rd, Singh KV, White AC Jr, Byrne L, Carmer A, Austin C, Graviss E, Stager C, Murray BE, Atmar RL. Sequential Outbreaks of Distinct Acinetobacter baumannii Strains in a Houston, Texas, Public Teaching Hospital. J Clin Microbiol, 2007. In Press
• Arias CA, Torres HA, Singh KV, Panesso D, Moore J, Wanger A, Murray BE. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis. 2007 Nov 15;45(10):1343-6, 2007.
• Kemp KD, Singh KV, Nallapareddy SR, Murray BE. Relative contributions of Enterococcus faecalis OG1RF sortase-encoding genes, srtA and bps (srtC), to biofilm formation and a murine model of urinary tract infection. Infect Immun. 2007 Nov;75(11):5399-404, 2007.
• Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother. 2007 Sep;60(3):594-8, 2007.
• Bourgogne A, Singh KV, Fox KA, Pflughoeft KJ, Murray BE, Garsin DA. EbpR is important for biofilm formation by activating expression of the endocarditis and biofilm-associated pilus operon (ebpABC) of Enterococcus faecalis OG1RF. J Bacteriol. 2007 Sep;189(17):6490-3, 2007.
• Singh KV, Nallapareddy SR, Murray BE. Importance of the ebp (endocarditis- and biofilm-associated pilus) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection. J Infect Dis. 2007 Jun 1;195(11):1671-7, 2007.
• Arias CA, Singh KV, Panesso D, Murray BE.Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates. Antimicrob Agents Chemother. 2007 Jun;51(6):2043-7, 2007.
• Nallapareddy SR, Singh KV, Sillanpaa J, Garsin DA, Hook M, Erlandsen SL, Murray BE. Endocarditis and biofilm-associated pili of Enterococcus faecalis. J Clin Invest. 2006;116(10):2799-2807.
• Tsigrelis C, Singh KV, Coutinho TD, Murray BE, Baddour LM. Vancomycin-Resistant Enterococcus faecalis Endocarditis: Linezolid Failure and Strain Characterization of Virulence Factors. J Clin Microbiol. 2006 Dec 20; [Epub ahead of print]
• Arias CA, Robredo B, Singh KV, Torres C, Panesso D, Murray BE. Rapid identification of Enterococcus hirae and Enterococcus durans by PCR and detection of a homologue of the E. hirae mur-2 Gene in E. durans. J Clin Microbiol. 2006; 44(4):1567-70.
• Nallapareddy SR, Singh KV, Murray BE. Construction of improved temperature-sensitive and mobilizable vectors and their use for constructing mutations in the adhesin-encoding acm gene of poorly transformable clinical Enterococcus faecium strains. Appl Environ Microbiol. 2006 Jan;72(1):334-45.
• Singh KV, Nallapareddy SR, Nannini EC, Murray BE. Fsr-independent production of protease(s) may explain the lack of attenuation of an Enterococcus faecalis fsr mutant versus a gelE-sprE mutant in induction of endocarditis. Infect Immun. 2005 Aug;73(8):4888-94.
• Nannini EC, Teng F, Singh KV, Murray BE. Decreased virulence of a gls24 mutant of Enterococcus faecalis OG1RF in an experimental endocarditis model. Infect Immun. 2005;73(11):7772-4.
• Singh KV and Murray BE. Differences in the Enterococcus faecalis lsa Locus that Influence Susceptibility to Quinupristin-Dalfopristin and Clindamycin. Antimicrob Agents Chemother. 2005 Jan;49(1):32-9
• Roberts JC, Singh KV, Okhuysen PC, Murray BE. Molecular epidemiology of the fsr locus and of gelatinase production among different subsets of Enterococcus faecalis isolates. J Clin Microbiol. 2004 May;42(5):2317-20.
• Nannini E.C., Singh KV, and Murray BE. Relapse of type A b-lactamase Producing Staphylococcus aureus Native Valve Endocarditis during Cefazolin Therapy: Revisiting the Issue. Clin Infect Dis.37(9):1194-8. 2003.
• Burman WJ, Breese PE, Murray BE, Singh KV, Batal HA, MacKenzie TD, Ogle JW, Wilson ML, Reves RR, Mehler PS. Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates. Am J Med. 2003 Oct 1;115(5):358-64.
• Pai SR, Singh KV, Murray BE. In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model. Antimicrob Agents Chemother. 2003 Aug;47(8):2706-9.
• Nannini EC, Pai SR, Singh KV, Murray BE. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model. Antimicrob Agents Chemother. 2003 Feb;47(2):529-32.
• Sifri CD, Mylonakis E, Singh KV, Qin X, Garsin DA, Murray BE, Ausubel FM, and Calderwood SB.Virulence effect of Enterococcus faecalis protease genes and the quorum-sensing locus fsr in Caenorhabditis elegans and mice. Infect Immun.70(10):5647-50, 2002
• Singh KV, Weinstock GM and Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycinand quinupristin-dalfopristin. Antimicrob Agents Chemother. 46(6):1845-50, 2002
• Teng F, Wang L, Singh KV, Murray BE and Weinstock GM. Involvement of PhoP-PhoS homologs in Enterococcus faecalis virulence. Infect Immun. 70(4):1991-6, 2002
• Nallapareddy SR, Duh RW, Singh KV and Murray BE. Molecular typing of selected Enterococcus faecalis isolates: pilot study using multilocus sequence typing and pulsed-field gel electrophoresis. J Clin Microbiol. 40(3):868-76, 2002.
• Singh, K. V., Malathum, K. and Murray, B. E.: In Vitro activity of a new ketolide, ABT-773, against multiresistant gram-positive cocci. Antimicrob Agents Chemother. 45 (12);3640-3643, 2001.
• Garsin, D. A., Sifri, C. D., Mylonakis, E., Qin, X., Singh, K. V., Murray, B. E., Calderwood, S. B., Ausubel, F. M.: A simple model host for identifying gram-positive virulence factors. Proc Natl Acad Sci USA. 98(19);10892-10897, 2001.
• Qin, X., Singh, K. V., Weinstock, G. M. and Murray, B. E.: Characterization of fsr, a regulator controlling expression of gelatinase and serine protease in Enterococcus faecalis OG1RF. J Bacteriol. 183(11): 3372-82, 2001.
• Duh, R. W., Singh, K. V., Malathum, K. and Murray, B. E.: In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. Microb Drug Resist. 7(1): 39-46, 2001.
• Robredo, B., Singh, K. V., Torres, C. and Murray, B. E.: Streptogramin resistance and shared pulsed-field gel electrophoresis patterns in vanA containing Enterococcus faecium and Enterococcus hirae isolated from human and animals in Spain. Microb Drug Resist. 6(4): 305-11, 2000.
• Singh, K. V., Malathum, K. and Murray, B. E.: Disruption of an Enterococus faecium species specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increased macrolide susceptibility. Antimicrob Agents Chemother. 45(1):263-6,2001.
• Singh, K. V., Zscheck, K. K. and Murray, B. E.: Efficacy of Telithromycin (HMR 3647) against Enterococci in a Mouse Peritonitis Model. Antimicrob Agents Chemother. 44(12):3434-7,2000.
• Robredo, B., Torres, C, Singh, K. V., and Murray, B. E.: Molecular analysis of Tn1546 in vanA-containing Enterococcus spp. Isolated from humans and poultry. Antimicrob Agents Chemother. 44(9):2588-9, 2000.
• Robredo, B., Singh, K. V., Baquero, F., Murray, B. E., and Torres, C,: Vancomycin resistant enterococci isolated from animals and food. Int J Food Microbiol. 54(3):197-204, 2000.
• Rakita RM, Quan VC, Jacques-Palaz K, Singh KV, Arduino RC, Mee M, Murray BE. Specific antibody promotes opsonization and PMN-mediated killing of phagocytosis-resistant Enterococcus faecium. FEMS Immunol Med Microbiol.28:291-9, 2000.
• XU, Y., Singh, K. V., Qin, X., Murray, B. E. and Weinstock, G. M.: Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis. Infect. Immun. 68: 815-823, 2000.
• Qin, X., Singh, K. V., Weinstock, G. M. and Murray, B. E.: Enterococcus faecalis homologs of agr genes and their effects on production of gelatinase and a serine protease. Infect Immun. 68: 2579-86, 2000.
• Nallapareddy, S. R., Singh, K. V., Duh, R.W., Weinstock, G. M. and Murray, B. E.: Diversity of ace, a gene encoding an MSCRAMM, from different strains of Enterococcus faecalis and evidence for production of ACE during human infections. Infect Immun. 68(9):5210-27, 2000.

Professional Organizations:

• American Society for Microbiology

(back to top)